Full text
Earnings transcript
Read the complete earnings call transcript.
AZN
AstraZeneca PLC
$203.49
2.76
(1.37%)
| Exchange: | NYSE |
| Market Cap: | 157.734B |
| Shares Outstanding: | 716.59M |
About The Company
| Sector: | Healthcare | |||||
| Industry: | Drug Manufacturers – General | |||||
| CEO: | Pascal Claude Roland Soriot | |||||
| Full Time Employees: | 94300 | |||||
| Address: |
| |||||
| Website: | https://www.astrazeneca.com |
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 45,811,000 | 54,073,000 | 58,739,000 |
| Gross Profit | 37,543,000 | 43,866,000 | 48,106,000 |
| EBITDA | 13,422,000 | 15,438,000 | 19,829,000 |
| Operating Income | 8,193,000 | 10,003,000 | 13,743,000 |
| Net Income | 5,955,000 | 7,035,000 | 10,255,000 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 101,119,000 | 104,035,000 | 114,074,000 |
| Total Liabilities | 61,953,000 | 63,164,000 | 65,355,000 |
| Total Stockholders Equity | 39,143,000 | 40,786,000 | 48,667,000 |
| Total Debt | 28,622,000 | 30,114,000 | 29,703,000 |
| Cash and Cash Equivalents | 5,840,000 | 5,488,000 | 5,711,000 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | 10,345,000 | 11,861,000 | 15,191,507 |
| Capital Expenditure | -3,778,000 | -4,586,000 | -2,810,000 |
| Free Cash Flow | 6,567,000 | 7,275,000 | 11,765,000 |
| Net Income | 6,899,000 | 8,691,000 | 10,225,000 |
| Net Change in Cash | -346,000 | -208,000 | 237,825 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Full Access | Full Access | Full Access | Full Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 78,680,592.244 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (High) | 84,688,368.562 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (Avg) | 82,476,800 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Low) | 40,773,237.511 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (High) | 43,886,540.090 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Avg) | 42,740,478.429 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Low) | 11,970,199.575 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (High) | 13,175,860.516 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Avg) | 12,732,033.836 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Low) | 30,577,347.842 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (High) | 32,912,127.754 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Avg) | 32,052,654.035 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Avg) | 16.300 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (High) | 16.870 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Low) | 15.330 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated Revenue) | 9 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated EPS) | 5 | Full Access | Full Access | Full Access | Full Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Robust Financial Performance: AZN demonstrates strong revenue growth and consistent net income as per the latest income statements, supported by positive free cash flow trends from cash flow statements. This indicates operational efficiency and financial stability, critical for sustaining long-term growth.
- Innovative Product Portfolio: Insights from earnings call transcripts and news highlight AZN’s focus on innovation in key therapeutic areas, driving revenue as evidenced by product segment data. This positions the company favorably within the pharmaceutical industry.
- Strong Market Position: With a competitive market cap and a solid presence in the global healthcare sector (as per company profile data), AZN benefits from brand recognition and a large employee base, enhancing its operational capacity.
Log in with Full Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
Common questions about AZN valuation
Is AstraZeneca PLC (AZN) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for AstraZeneca PLC (AZN) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is AZN a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether AZN trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is AZN’s P/E ratio?
You can see AZN’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for AZN?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is AZN a good long-term investment?
Whether AZN fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
AZN
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
1.37
Trading Metrics:
| Open: | 199.67 | Previous Close: | 200.73 | |
| Day Low: | 199.23 | Day High: | 204.34 | |
| Year Low: | 122.48 | Year High: | 212.71 | |
| Price Avg 50: | 194.72 | Price Avg 200: | 171.71 | |
| Volume: | 1.919M | Average Volume: | 2.352M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's freeAZN full analysis
Hey everyone, welcome back to the channel! Today, we’re diving deep into a comprehensive analysis of AstraZeneca, ticker AZN, one of the heavyweights in the global pharmaceutical space. If you’re looking to understand what makes this company tick, whether it’s a solid investment for your portfolio, or just curious about its future prospects, you’re in the right place. Let’s break it all down together, so stick around and let’s get started! Alright, before we get into the nitty-gritty, let’s set…
Relevant news
